Skip to main content

Table 1 Patient characteristics

From: Nocturnal CPAP improves walking capacity in COPD patients with obstructive sleep apnoea

 

Overlap syndrome n = 22

COPD n = 22

p-value

Age

70.0 ± 8.3

71.7 ± 8.5

0.495

Male, n (%)

21 (96.7)

22 (100)

0.999

BMI

24.9 ± 3.5

22.9 ± 3.0

0.054

Smoking, pack-years

52.3 ± 21.5

50.8 ± 26.4

0.837

ESS

12.7 ± 4.5

8.3 ± 3.5

0.004

PSQ

11.8 ± 4.0

7.5 ± 3.7

0.001

Emphysema predominant, n (%)

5 (22.7)

14 (63.6)

0.014

Pulmonary function test

   

FEV1/FVC

57.5 ± 12.7

54.5 ± 9.6

0.197

FEV1 (L)

1.09 ± 0.51

0.95 ± 0.45

0.227

FEV1 (% predicted)

52.7 ± 28.6

45.1 ± 19.2

0.431

FVC (L)

1.87 ± 0.69

1.70 ± 0.60

0.348

FVC (% predicted)

63.3 ± 25.1

57.2 ± 21.7

0.378

Arterial blood gas

   

pH

7.4 ± 0.0

7.4 ± 0.0

0.672

PaCO2 (mm Hg)

41.8 ± 3.8

40.6 ± 3.8

0.354

PaO2 (mmHg)

77.5 ± 11.9

79.2 ± 9.0

0.581

Medication

   

LABA + ICS, n (%)

20 (90.9)

19 (86.4)

0.565

LAMA, n (%)

18 (81.8)

17 (77.3)

0.907

Theophyllines, n (%)

6 (27.3)

2 (9.1)

0.375

Comorbidities

   

DM, n (%)

0 (0)

1 (4.5)

-

HTN, n (%)

10 (45.4)

8 (36.4)

0.348

CAD, n (%)

1 (4.5)

1 (4.5)

0.823

PAOD, n (%)

0 (0)

0 (0)

-

  1. Data are presented as mean ± SD, or number (percentage).
  2. BMI body mass index, ESS Epworth sleepiness scale, PSQ Pittsburg sleep quality, FEV1 forced expiratory volume in one second, FVC forced volume capacity, ICS inhaled corticosteroids, LABA long-acting β2 agonist, LAMA long-acting muscarinic antagonist, DM diabetes mellitus, HTN hypertension, CAD coronary artery disease, PAOD peripheral arterial occlusion disease.
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us